Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil.

@article{Zhou2006PharmacokineticsOT,
  title={Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil.},
  author={X M Zhou and Barbara A Fielman and Deborah M Lloyd and George C Chao and Nathaniel A. Brown},
  journal={Antimicrobial agents and chemotherapy},
  year={2006},
  volume={50 7},
  pages={2309-15}
}
Two phase I studies were conducted to assess the plasma pharmacokinetics of telbivudine and potential drug-drug interactions between telbivudine (200 or 600 mg/day) and lamivudine (100 mg/day) or adefovir dipivoxil (10 mg/day) in healthy subjects. Study drugs were administered orally. The pharmacokinetics of telbivudine were characterized by rapid absorption with biphasic disposition. The maximum concentrations in plasma (Cmax) were reached at median times ranging from 2.5 to 3.0 h after dosing… CONTINUE READING
7 Citations
23 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 23 references

and Drug Administration

  • U. S. Foo
  • 2005. CDER drug and biologic approvals for…
  • 2005
1 Excerpt

Clinical pharmacokinetics of telbivudine, a potent antiviral for hepatitis B, in subjects with impaired hepatic or renal function

  • X. J. Zhou, M. Myers, G. Chao, G. Dubuc, N. A. Brown
  • 55th Annu. Meet. Am. Assoc. Study Liver Dis…
  • 2004
1 Excerpt

Similar Papers

Loading similar papers…